CLL immunotoxins

Arthur E. Frankel, Robert J. Kreitman

Research output: Contribution to journalEditorialpeer-review

9 Scopus citations


Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB 486 IL2, DAB 389 IL2, RFB4 (dsFv)-PE38 and anti-Tac(Fv)-PE38. Remissions have occurred in some patients without significant myelosuppression, but novel agents continue to be needed. Kay and co-workers in this issue of Leukemia Research have targeted interleukin-4 receptors (IL4R) on CLL B cells with a recombinant IL4 pseudomonas exotoxin fusion protein (IL-4(38-37)-PE38KDEL). A fraction of patients (19%) had CLL cells that were extremely sensitive to the immunotoxin. This novel agent may provide an important new therapeutic for use in the treatment of CLL.

Original languageEnglish (US)
Pages (from-to)985-986
Number of pages2
JournalLeukemia Research
Issue number9
StatePublished - Sep 2005


  • CLL
  • Immunotoxins
  • Leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'CLL immunotoxins'. Together they form a unique fingerprint.

Cite this